ImmunityBio
IBRX | NASDAQ
$5.98
-$0.04 (-0.66%)
At close: Nov 16, 2026, 4:00 PM ET
$5.93
-$0.05 (-0.84%)
After-hours:
Nov 16, 2026, 7:52 PM ET
ImmunityBio Company Profile
Company profile explainedCompany Profile
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Key Executives
| Name | Position |
|---|---|
| Richard Gerald Adcock | President, Chief Executive Officer & Director |
| David C. Sachs | Chief Financial Officer |
| Enrique Diloné | Chief Technology Officer |
| Barry J. Simon | Chief Corporation Affairs Officer & Director |
| Emily Arison | Senior Vice President of Human Resources |
| Hans Georg Klingemann | Chief Science Officer of Cellular |
| Leonard S. Sender | Chief Medical Officer of Liquid Tumors & Cell Therapy |
| Patrick Soon-Shiong FRCS | Founder, Executive Chairman and Global Chief Scientific & Medical Officer |
| Regan J. Lauer | Chief Accounting Officer |
| Sandeep K. Reddy | Chief Medical Officer |
| Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 14, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 4 | Filing |
| Oct 06, 2026 | 4 | Filing |
| Aug 06, 2026 | SC 13D/A | [Amend] Filing |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 06, 2026 | 4 | Filing |
| Jul 06, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
ImmunityBio
| Country | United States |
| IPO Date | Jul 28, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 688 |
| CEO | Richard Gerald Adcock |
Contact Details
3530 John Hopkins Court San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | IBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326110 |
| CUSIP Number | 45256X103 |
| ISIN Number | US45256X1037 |
| SIC Code | 2836 |
Recent News
- 17 hours ago / seekingalpha.comImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
- 5 days ago / businesswire.comNew U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care
- 6 days ago / businesswire.comImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
- 6 days ago / zacks.comIBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%
- 7 days ago / fool.comWhy ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
- 8 days ago / benzinga.comImmunityBio Reports Wider Quarterly Loss
- 8 days ago / zacks.comImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates
- 8 days ago / businesswire.comImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
- 8 days ago / businesswire.comImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
- 8 days ago / businesswire.comImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
Add to Watchlist
Select watchlists to add or remove IBRX